支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌的疗效观察  

The Efficacy of Bronchial Arterial Infusion Combined with Systemic Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer

作　　者：李肖燕[1] 王振杰[2] 王玉然[1] 成丛丛 代一佳 李贵新[1] 

机构地区：[1]潍坊医学院肿瘤学教研室,山东潍坊261053 [2]潍坊市人民医院医疗部

出　　处：《潍坊医学院学报》2016年第3期203-205,共3页Acta Academiae Medicinae Weifang

摘　　要：目的探讨支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法62例晚期中心型非小细胞肺癌患者作为研究对象,随机将患者分为支气管动脉灌注联合全身化疗组(A组,n=31)和全身化疗组(B组,n=31),观察治疗前后近期疗效、1年生存率、毒副反应。结果 A组缓解率明显高于B组(P<0.05)。随访6个月,A组死亡病例明显低于B组(P<0.05),但两组1年生存率比较差异无显著性(P>0.05)。联合治疗未增加治疗的毒性反应。结论支气管动脉灌注联合全身化疗治疗晚期非小细胞肺癌疗效好,不良反应可耐受。Objective To observe the effect and adverse effects of bronchial arterial infusion combined with systemic chemotherapy for patients with advanced non-small cell Lung cancer（ NSCLC）. Methods Sixty-two patients were randomly divided into two groups by bronchial arterial infusion combined with systemic chemotherapy group（ group A,n = 31） and systemic chemotherapy group（ group B,n = 31）,then compared with the overall response rate（ ORR）,one year survival rate and adverse effects between the two groups. Results There are significant difference between the two groups in the ORR and 6 months mortality（P〈0. 05）,but no significant difference in one year survival rate and side reactions（P〈0. 05）. Conclusion Bronchial arterial infusion combined with systemic chemotherapy is highly effective for advanced NSCLC,and cuase tolerated adverse effects.

关 键 词：支气管动脉灌注 全身化疗 非小细胞肺肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]